US expanded label for UCB anti-epileptic 'a reflection of patient centric culture'
This article was originally published in Scrip
Executive Summary
The US FDA has approved UCB's anti-epileptic Keppra (levetiracetam) tablets and oral solution as adjunctive therapy in the treatment of partial onset seizures in adults and children one month of age and older with epilepsy – an expanded indication.